|
1
|
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
|
J Clin Oncol
|
1999
|
9.22
|
|
2
|
Hypersensitivity reactions from taxol.
|
J Clin Oncol
|
1990
|
3.83
|
|
3
|
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.
|
Cancer Res
|
1988
|
1.84
|
|
4
|
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
|
J Clin Oncol
|
1993
|
1.76
|
|
5
|
Metastatic carcinoma involving the testis. Clinical and pathologic distinction from primary testicular neoplasms.
|
Cancer
|
1984
|
1.71
|
|
6
|
Cutaneous involvement in malignant histiocytosis. Case report and review of the literature.
|
Arch Dermatol
|
1981
|
1.64
|
|
7
|
Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.
|
J Clin Oncol
|
1993
|
1.50
|
|
8
|
Clinical features and natural history of intramedullary spinal cord metastasis.
|
Cancer
|
1985
|
1.43
|
|
9
|
Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.
|
Clin Cancer Res
|
2000
|
1.40
|
|
10
|
Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.
|
Clin Cancer Res
|
2001
|
1.35
|
|
11
|
1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo.
|
Cancer Res
|
1999
|
1.27
|
|
12
|
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
|
Urology
|
1997
|
1.24
|
|
13
|
Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.
|
Cancer Res
|
1997
|
1.20
|
|
14
|
Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1.
|
J Biol Chem
|
2001
|
1.19
|
|
15
|
Importance of continued testicular suppression in hormone-refractory prostate cancer.
|
J Clin Oncol
|
1993
|
1.18
|
|
16
|
High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.
|
J Clin Oncol
|
1992
|
1.15
|
|
17
|
Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men.
|
Metabolism
|
2001
|
1.15
|
|
18
|
Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.
|
Clin Cancer Res
|
2001
|
1.15
|
|
19
|
Phase I study of vinblastine and verapamil given by concurrent iv infusion.
|
Cancer Treat Rep
|
1985
|
1.15
|
|
20
|
Acquired extrinsic pulmonic stenosis caused by mediastinal tumors.
|
Cancer
|
1982
|
1.13
|
|
21
|
A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.
|
Clin Cancer Res
|
1999
|
1.12
|
|
22
|
Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling.
|
Clin Cancer Res
|
2001
|
1.09
|
|
23
|
Factors influencing options in primary breast cancer treatment.
|
J Clin Oncol
|
1987
|
1.07
|
|
24
|
Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature.
|
J Clin Oncol
|
1992
|
1.05
|
|
25
|
Bromide intoxication.
|
Johns Hopkins Med J
|
1976
|
1.04
|
|
26
|
A phase II study of taxol in patients with malignant melanoma.
|
Invest New Drugs
|
1991
|
1.04
|
|
27
|
The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase.
|
J Clin Endocrinol Metab
|
1982
|
1.01
|
|
28
|
Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment.
|
Urol Clin North Am
|
1992
|
1.00
|
|
29
|
Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer.
|
Urol Oncol
|
2011
|
0.99
|
|
30
|
Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo.
|
J Urol
|
2001
|
0.98
|
|
31
|
Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone.
|
J Natl Cancer Inst
|
1998
|
0.97
|
|
32
|
Spinal cord compression in prostate cancer.
|
J Neurooncol
|
1995
|
0.97
|
|
33
|
Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography.
|
Am J Med
|
1982
|
0.95
|
|
34
|
Choice of starting dose and escalation for phase I studies of antitumor agents.
|
Cancer Chemother Pharmacol
|
1992
|
0.94
|
|
35
|
Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement.
|
Cancer
|
1982
|
0.94
|
|
36
|
Metastatic Leydig cell tumor of the testis. Report of three cases and review of the literature.
|
Cancer
|
1986
|
0.93
|
|
37
|
'Sarcoidosis' and sarcoid-like lesions. Their occurrence after cytotoxic and radiation therapy of testis cancer.
|
Arch Intern Med
|
1981
|
0.93
|
|
38
|
Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues.
|
Biochem Pharmacol
|
1996
|
0.91
|
|
39
|
Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
|
Cancer Treat Rep
|
1987
|
0.89
|
|
40
|
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.
|
Clin Cancer Res
|
1996
|
0.89
|
|
41
|
Gynecomastia in men following antineoplastic therapy.
|
Arch Intern Med
|
1982
|
0.88
|
|
42
|
Serious hyponatremia in patients with cancer: management with demeclocycline.
|
Cancer
|
1981
|
0.88
|
|
43
|
Important clinical pharmacologic considerations in the use of methadone in cancer patients.
|
Cancer Treat Rep
|
1979
|
0.88
|
|
44
|
CSF infections complicating the management of neoplastic meningitis. Clinical features and results of therapy.
|
Arch Intern Med
|
1982
|
0.86
|
|
45
|
Discordance between plasma calcitonin and tumor-cell mass in medullary thyroid carcinoma.
|
N Engl J Med
|
1979
|
0.86
|
|
46
|
A phase II trial of CI-958 in patients with hormone-refractory prostate cancer.
|
Cancer Chemother Pharmacol
|
1999
|
0.86
|
|
47
|
Ectopic adrenocorticotrophic (ACTH) syndrome and small cell carcinoma of the lung-assessment of clinical implications in patients on combination chemotherapy.
|
Cancer
|
1981
|
0.84
|
|
48
|
Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
|
J Clin Oncol
|
1987
|
0.84
|
|
49
|
Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion.
|
Cancer
|
1986
|
0.84
|
|
50
|
Anaerobic liver abscess and intrahepatic metastases: a case report and review of the literature.
|
Cancer
|
1978
|
0.84
|
|
51
|
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
|
Cancer Res
|
1992
|
0.84
|
|
52
|
Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials.
|
Cancer Epidemiol Biomarkers Prev
|
1996
|
0.84
|
|
53
|
Modulation of 5-iodo-2'-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines.
|
Biochem Pharmacol
|
1985
|
0.82
|
|
54
|
Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.
|
Cancer Res
|
1989
|
0.82
|
|
55
|
Inadvertent administration of 480 mg/m2 of cisplatin.
|
Am J Med
|
1989
|
0.82
|
|
56
|
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
|
J Clin Oncol
|
1987
|
0.81
|
|
57
|
Vitamin D in the prevention and treatment of prostate cancer.
|
Semin Urol Oncol
|
1999
|
0.81
|
|
58
|
Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.
|
Prostate Cancer Prostatic Dis
|
2007
|
0.81
|
|
59
|
Watery diarrhea syndrome in an adult with ganglioneuroma-pheochromocytoma: identification of vasoactive intestinal peptide, calcitonin, and catecholamines and assessment of their biologic activity.
|
Cancer
|
1977
|
0.81
|
|
60
|
Population pharmacokinetics of hydroxyurea in cancer patients.
|
Cancer Chemother Pharmacol
|
1995
|
0.81
|
|
61
|
All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes.
|
Cancer Chemother Pharmacol
|
1998
|
0.81
|
|
62
|
Richter's syndrome: diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature.
|
Am J Med
|
1980
|
0.81
|
|
63
|
Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
|
Cancer Res
|
1985
|
0.80
|
|
64
|
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
|
J Clin Oncol
|
1994
|
0.80
|
|
65
|
TNF-alpha protects dendritic cells from prostate cancer-induced apoptosis.
|
Prostate Cancer Prostatic Dis
|
2001
|
0.80
|
|
66
|
Management of primary germ cell tumors of the mediastinum.
|
J Thorac Cardiovasc Surg
|
1982
|
0.80
|
|
67
|
Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
|
Cancer Res
|
1994
|
0.80
|
|
68
|
Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study.
|
J Urol
|
1990
|
0.80
|
|
69
|
Phase II trial of etoposide in advanced prostate cancer.
|
Cancer Treat Rep
|
1984
|
0.79
|
|
70
|
Ectopic hormone syndromes.
|
Cancer Invest
|
1986
|
0.79
|
|
71
|
A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.
|
Cancer Res
|
1991
|
0.79
|
|
72
|
Complications of hepatic arterial infusion chemotherapy.
|
Radiographics
|
1991
|
0.79
|
|
73
|
A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer.
|
Invest New Drugs
|
1996
|
0.79
|
|
74
|
The effects of L-dopa on in vitro and in vivo calcitonin release from medullary thyroid carcinoma.
|
J Clin Endocrinol Metab
|
1979
|
0.78
|
|
75
|
Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
|
Cancer Res
|
1990
|
0.78
|
|
76
|
Frequency of abnormalities of cortisol secretion and water metabolism in patients with small cell carcinoma of the lung and other malignancies.
|
Chest
|
1982
|
0.78
|
|
77
|
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.78
|
|
78
|
Phase II trial of carboplatin in soft-tissue sarcoma.
|
Am J Clin Oncol
|
1990
|
0.78
|
|
79
|
Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.
|
Cancer Chemother Pharmacol
|
1994
|
0.78
|
|
80
|
Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms.
|
Cancer Treat Rep
|
1985
|
0.78
|
|
81
|
Phase II study of echinomycin in the treatment of renal cell carcinoma ECOG study E2885.
|
Invest New Drugs
|
1994
|
0.77
|
|
82
|
A phase I trial of high-dose oral tamoxifen and CHOPE.
|
Cancer Chemother Pharmacol
|
1995
|
0.77
|
|
83
|
Psychological distress among women with breast problems.
|
Cancer
|
1986
|
0.77
|
|
84
|
Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate.
|
Ann Surg Oncol
|
1995
|
0.77
|
|
85
|
Psychological and mood disturbance associated with the diagnosis and treatment of testis cancer and other malignancies.
|
J Clin Psychol
|
1990
|
0.77
|
|
86
|
Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
|
Clin Cancer Res
|
1997
|
0.77
|
|
87
|
Computerized tomography and lymphangiography in staging testis tumors.
|
J Urol
|
1981
|
0.76
|
|
88
|
Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease.
|
Johns Hopkins Med J
|
1977
|
0.76
|
|
89
|
Biological and clinical effects of interferon-beta ser at two doses.
|
J Interferon Res
|
1990
|
0.76
|
|
90
|
Effects of cytokines on the pituitary-adrenal axis in cancer patients.
|
J Interferon Res
|
1993
|
0.76
|
|
91
|
A phase I trial of high-dose continuous-infusion hydroxyurea.
|
Cancer Chemother Pharmacol
|
1993
|
0.76
|
|
92
|
Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
|
J Urol
|
1988
|
0.76
|
|
93
|
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
|
Vet Comp Oncol
|
2010
|
0.76
|
|
94
|
An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.
|
Cancer
|
1994
|
0.76
|
|
95
|
Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases.
|
J Clin Oncol
|
1991
|
0.76
|
|
96
|
5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group.
|
Invest New Drugs
|
1994
|
0.76
|
|
97
|
Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer.
|
Cancer Treat Res
|
1988
|
0.76
|
|
98
|
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
|
Cancer Chemother Pharmacol
|
1992
|
0.75
|
|
99
|
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.
|
Invest New Drugs
|
1988
|
0.75
|
|
100
|
Quinacrine ochronosis and rheumatoid arthritis.
|
JAMA
|
1976
|
0.75
|
|
101
|
Update on Dx and management of bladder cancer.
|
Geriatrics
|
1982
|
0.75
|
|
102
|
Renal cell carcinoma: considerations for nephron-sparing surgery.
|
Urology
|
1995
|
0.75
|
|
103
|
A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma.
|
Invest New Drugs
|
1995
|
0.75
|
|
104
|
High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.
|
Cancer Treat Rep
|
1987
|
0.75
|
|
105
|
Megestrol acetate in the treatment of hormone refractory prostate cancer.
|
Am J Clin Oncol
|
1997
|
0.75
|
|
106
|
Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma.
|
Cancer Treat Rep
|
1987
|
0.75
|
|
107
|
Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.
|
Cancer Chemother Pharmacol
|
1993
|
0.75
|
|
108
|
Nephrotoxicity with cisplatin and antihypertensive medications.
|
Ann Intern Med
|
1982
|
0.75
|
|
109
|
Lymphoma and cancer of the testis.
|
N Engl J Med
|
1980
|
0.75
|
|
110
|
Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma.
|
Cancer Treat Rep
|
1984
|
0.75
|
|
111
|
Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate.
|
Cancer Treat Rep
|
1982
|
0.75
|
|
112
|
Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer.
|
Med Pediatr Oncol
|
1981
|
0.75
|
|
113
|
"Eight-drugs-in-one-day" chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas.
|
Cancer
|
1989
|
0.75
|
|
114
|
Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.
|
Invest New Drugs
|
1994
|
0.75
|
|
115
|
Clinical chemosensitization by misonidazole and related compounds: a critical evaluation.
|
J Clin Oncol
|
1988
|
0.75
|
|
116
|
Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion.
|
Cancer Res
|
1988
|
0.75
|
|
117
|
Eight-drugs-in-one-day chemotherapy in postirradiated adult patients with malignant gliomas.
|
Med Pediatr Oncol
|
1989
|
0.75
|
|
118
|
Phase II evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer.
|
Cancer
|
1986
|
0.75
|
|
119
|
Phase I clinical trial and pharmacokinetic evaluation of acodazole (NSC 305884), an imidazoquinoline derivative with electrophysiological effects on the heart.
|
Cancer Res
|
1987
|
0.75
|
|
120
|
Epidermolysis bullosa acquisita. Association with amyloidosis and multiple myeloma.
|
JAMA
|
1980
|
0.75
|
|
121
|
Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer.
|
Wis Med J
|
1988
|
0.75
|
|
122
|
Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma. An ECOG pilot study.
|
Invest New Drugs
|
1992
|
0.75
|
|
123
|
Phase II evaluation of menogaril in advanced prostate cancer: Eastern Cooperative Oncology Group EST P-A885.
|
Am J Clin Oncol
|
2001
|
0.75
|
|
124
|
Massive skeletal muscle invasion by lymphoma.
|
Arch Intern Med
|
1985
|
0.75
|
|
125
|
Reversible increase in serum alpha-fetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma.
|
J Clin Oncol
|
1986
|
0.75
|
|
126
|
Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity.
|
Cancer Immunol Immunother
|
1997
|
0.75
|
|
127
|
Phase II study of amsacrine (AMSA) in previously treated patients with advanced transitional cell carcinoma of the urothelium: a National Bladder Cancer Collaborative Group A study.
|
Cancer Treat Rep
|
1983
|
0.75
|
|
128
|
Electronic cancer Munchausen syndrome.
|
Ann Intern Med
|
1998
|
0.75
|
|
129
|
A pilot study of short-course, high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin's lymphomas.
|
Am J Clin Oncol
|
1989
|
0.75
|
|
130
|
Painful gynecomastia following cytotoxic therapy for testis cancer: a potentially favorable prognostic sign?
|
J Clin Oncol
|
1983
|
0.75
|
|
131
|
Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
|
Urology
|
1985
|
0.75
|
|
132
|
Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial.
|
Invest New Drugs
|
1992
|
0.75
|